William B. Tabayoyong, M.D., Ph.D.

Locations

601 Elmwood Avenue, 2nd Floor
Rochester, NY 14642

158 Sawgrass Drive, 2nd Floor, Suite 230
Rochester, NY 14620

About Me

Dr. Tabayoyong is a Urologic Oncologist who specializes in both minimally invasive urologic oncology (robotic surgery of the bladder, prostate, and kidney cancers) and advanced open pelvic and retroperitoneal cancer surgery. Dr. Tabayoyong has clinical expertise in all aspects of general urology wit...

Dr. Tabayoyong is a Urologic Oncologist who specializes in both minimally invasive urologic oncology (robotic surgery of the bladder, prostate, and kidney cancers) and advanced open pelvic and retroperitoneal cancer surgery. Dr. Tabayoyong has clinical expertise in all aspects of general urology with special emphasis on the following: Bladder Cancer, Prostate Cancer, Kidney Cancer, Testicular Cancer, Penile Cancer.

Dr. Tabayoyong received his medical degree and PhD in Immunology at the University of Iowa’s Carver College of Medicine Medical Scientist Training Program at the University of Iowa in Iowa City, Iowa in 2011. He completed his urology residency at Case Western Reserve University School of Medicine in Cleveland, Ohio, in 2017. Following residency, he completed a two-year Society of Urologic Oncology fellowship at the University of Texas, MD Anderson Cancer Center in Houston, Texas, in 2019. His research interest is in Immunotherapy for urologic cancers, with primary focus on bladder cancer.

Certified Specialties

Urology - American Board of Urology

Credentials

Residency & Fellowship

Fellowship, Urologic Oncology, University of Texas MD Anderson Cancer Center. 2017 - 2019

Residency, Urology, University Hospitals Cleveland Medical Center. 2012 - 2017

Internship, Surgery (General Surgery), University Hospitals Cleveland Medical Center. 2011 - 2012

Education

MD | University Of Iowa Roy J & Lucille A Carver College Of Medicine. 2011

Publications

Journal Articles

Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members.

Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM

Urologic oncology.. 2020 May 16 Epub 05/16/2020.

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM

European urology oncology.. 2019 May 2 (3):286-293. Epub 09/10/2018.

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.

Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM

European urology.. 2019 January 75 (1):8-10. Epub 10/06/2018.

Current Use and Promise of Urinary Markers for Urothelial Cancer.

Tabayoyong W, Kamat AM

Current urology reports.. 2018 October 1719 (12):96. Epub 10/17/2018.

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.

Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB

European urology focus.. 2018 July 4 (4):512-521. Epub 09/03/2018.

Evaluating the impact of the genitourinary multidisciplinary tumour board: Should every cancer patient be discussed as standard of care?

Scarberry K, Ponsky L, Cherullo E, Larchian W, Bodner D, Cooney M, Ellis R, Maclennan G, Johnson B, Tabayoyong W, Abouassaly R

Canadian Urological Association journal = Journal de l'Association des urologues du Canada.. 2018 May 14 Epub 05/14/2018.

The emerging role of immunotherapy in advanced urothelial cancers.

Tabayoyong W, Gao J

Current opinion in oncology.. 2018 May 30 (3):172-180. Epub 1900 01 01.

Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.

Tabayoyong W, Li R, Gao J, Kamat A

The Urologic clinics of North America.. 2018 May 45 (2):155-167. Epub 02/21/2018.

Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.

Yu AC, Badve C, Ponsky LE, Pahwa S, Dastmalchian S, Rogers M, Jiang Y, Margevicius S, Schluchter M, Tabayoyong W, Abouassaly R, McGivney D, Griswold MA, Gulani V

Radiology.. 2017 June 283 (3):729-738. Epub 02/10/2017.

Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival.

Minnillo BJ, Tabayoyong W, Francis JJ, Maurice MJ, Zhu H, Kim S, Abouassaly R

Canadian Urological Association journal = Journal de l'Association des urologues du Canada.. 2017 May 11 (5):E184-E191. Epub 05/09/2017.

Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal Masses.

Tabayoyong W, Abouassaly R, Kiechle JE, Cherullo EE, Meropol NJ, Shah ND, Dong S, Thompson RH, Smaldone MC, Zhu H, Ialacci S, Kim SP

The Journal of urology.. 2015 December 194 (6):1548-53. Epub 06/19/2015.

Prostate Cancer Screening and the Associated Controversy.

Tabayoyong W, Abouassaly R

The Surgical clinics of North America.. 2015 October 95 (5):1023-39. Epub 06/23/2015.

Books

Netter's Surgical Anatomy and Approaches (2014)

Chapter: Radical Prostatectomy

Authors: Conor P. Delaney

Publisher: Elsevier, Philadelphia, PA 2014

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.